Medifast (NYSE:MED) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Medifast (NYSE:MED) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $16.50.

Medifast Price Performance

MED opened at $10.91 on Friday. Medifast has a 1 year low of $10.36 and a 1 year high of $21.98. The stock has a 50-day moving average price of $12.17 and a 200-day moving average price of $13.26. The firm has a market cap of $119.85 million, a PE ratio of 1,090.50 and a beta of 0.48.

Medifast (NYSE:MED) last released its quarterly earnings data on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.20). The business had revenue of $89.41 million during the quarter, compared to the consensus estimate of $84.10 million. Medifast had a net margin of 0.06% and a negative return on equity of 0.89%. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS. As a group, sell-side analysts anticipate that Medifast will post 0.51 EPS for the current year.

Institutional Investors Weigh In On Medifast

Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its stake in shares of Medifast by 132.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer’s stock valued at $3,580,000 after buying an additional 151,434 shares during the period. Benjamin Edwards Inc. increased its position in Medifast by 75.0% during the 1st quarter. Benjamin Edwards Inc. now owns 24,419 shares of the specialty retailer’s stock valued at $329,000 after purchasing an additional 10,469 shares during the period. Nuveen LLC bought a new stake in shares of Medifast in the 1st quarter valued at about $407,000. Russell Investments Group Ltd. raised its holdings in shares of Medifast by 114.1% in the 1st quarter. Russell Investments Group Ltd. now owns 19,514 shares of the specialty retailer’s stock valued at $267,000 after purchasing an additional 10,401 shares in the last quarter. Finally, State of Wyoming lifted its position in shares of Medifast by 184.1% in the 1st quarter. State of Wyoming now owns 32,137 shares of the specialty retailer’s stock worth $433,000 after purchasing an additional 20,825 shares during the period. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.